icone plus
Contact Abonnez-vous aux actualités
Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
no clinical added value
EYLEA does not provide any improvement in actual benefit (level V, non-existent) compared with LUCENTIS for adults in the treatment of visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO).
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
wdWG8Gm92YZG7rxe
Listen
